<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39409131</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>In Silico Design of miniACE2 Decoys with In Vitro Enhanced Neutralization Activity against SARS-CoV-2, Encompassing <i>Omicron Subvariants</i>.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10802</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910802</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has overwhelmed healthcare systems and triggered global economic downturns. While vaccines have reduced the lethality rate of SARS-CoV-2 to 0.9% as of October 2024, the continuous evolution of variants remains a significant public health challenge. Next-generation medical therapies offer hope in addressing this threat, especially for immunocompromised individuals who experience prolonged infections and severe illnesses, contributing to viral evolution. These cases increase the risk of new variants emerging. This study explores miniACE2 decoys as a novel strategy to counteract SARS-CoV-2 variants. Using in silico design and molecular dynamics, blocking proteins (BPs) were developed with stronger binding affinity for the receptor-binding domain of multiple variants than naturally soluble human ACE2. The BPs were expressed in <i>E. coli</i> and tested in vitro, showing promising neutralizing effects. Notably, miniACE2 BP9 exhibited an average IC<sub>50</sub> of 4.9 µg/mL across several variants, including the Wuhan strain, Mu, Omicron BA.1, and BA.2 This low IC50 demonstrates the potent neutralizing ability of BP9, indicating its efficacy at low concentrations.Based on these findings, BP9 has emerged as a promising therapeutic candidate for combating SARS-CoV-2 and its evolving variants, thereby positioning it as a potential emergency biopharmaceutical.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arévalo-Romero</LastName><ForeName>Jenny Andrea</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Unidad de Ingeniería Celular y Molecular, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, IDCBIS, Bogotá 111611, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Errores Innatos del Metabolismo, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Cantillo</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unidad de Ingeniería Celular y Molecular, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, IDCBIS, Bogotá 111611, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Jiménez</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unidad de Ingeniería Celular y Molecular, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, IDCBIS, Bogotá 111611, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcos-Alcalde</LastName><ForeName>Íñigo</ForeName><Initials>Í</Initials><Identifier Source="ORCID">0000-0002-0674-6423</Identifier><AffiliationInfo><Affiliation>Grupo de Modelado Molecular del Centro de Biología Molecular Severo Ochoa, 14 CSIC-UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ros-Pardo</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Grupo de Modelado Molecular del Centro de Biología Molecular Severo Ochoa, 14 CSIC-UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camacho</LastName><ForeName>Bernardo Armando</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0001-5517-4188</Identifier><AffiliationInfo><Affiliation>Unidad de Ingeniería Celular y Molecular, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, IDCBIS, Bogotá 111611, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez-Puertas</LastName><ForeName>Paulino</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3131-729X</Identifier><AffiliationInfo><Affiliation>Grupo de Modelado Molecular del Centro de Biología Molecular Severo Ochoa, 14 CSIC-UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramírez-Segura</LastName><ForeName>Cesar A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-2687-9880</Identifier><AffiliationInfo><Affiliation>Unidad de Ingeniería Celular y Molecular, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, IDCBIS, Bogotá 111611, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>(Contract 057-2022, ID 9796).</GrantID><Agency>Agencia Distrital de Educación Superior, Ciencia y Tecnología (ATENEA), Bogotá D.C., Colombia</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2-decoys</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants evading monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">basic science for translational medicine</Keyword><Keyword MajorTopicYN="N">in silico design of next-generation therapies for infectious diseases</Keyword><Keyword MajorTopicYN="N">miniACE2</Keyword><Keyword MajorTopicYN="N">next-generation treatments for SARS-CoV-2</Keyword></KeywordList><CoiStatement>The funders had no role in the design of the study, interpretation of data, writing of the manuscript, or the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39409131</ArticleId><ArticleId IdType="pmc">PMC11476394</ArticleId><ArticleId IdType="doi">10.3390/ijms251910802</ArticleId><ArticleId IdType="pii">ijms251910802</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105924</ArticleId><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Guo J., Wang C., Luo F., Yu X., Zhang W., Li J., Zhao D., Xu D., Gong Q., et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. Lancet. 2020;395:809–815. doi: 10.1016/S0140-6736(20)30360-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30360-3</ArticleId><ArticleId IdType="pmc">PMC7159281</ArticleId><ArticleId IdType="pubmed">32151335</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y.-R., Cao Q.-D., Hong Z.-S., Tan Y.-Y., Chen S.-D., Jin H.-J., Tan K.-S., Wang D.-Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—An update on the status. Mil. Med. Res. 2020;7:11. doi: 10.1186/s40779-020-00240-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-020-00240-0</ArticleId><ArticleId IdType="pmc">PMC7068984</ArticleId><ArticleId IdType="pubmed">32169119</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Cases|WHO COVID-19 Dashboard.  [(accessed on 1 October 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Yu Y., Xu Y., Jian F., Song W., Yisimayi A., Wang P., Wang J., Liu J., Yu L., et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 2024;24:e70–e72. doi: 10.1016/S1473-3099(23)00744-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00744-2</ArticleId><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett J.D.S., Gravel A., Dubuc I., Gudimard L., Dos Santos Pereira Andrade A.C., Lacasse É., Fortin P., Liu J.-L., Cervantes J.A., Galvez J.H., et al. SARS-CoV-2 rapidly evolves lineage-specific phenotypic differences when passaged repeatedly in immune-naïve mice. Commun. Biol. 2024;7:191. doi: 10.1038/s42003-024-05878-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-024-05878-3</ArticleId><ArticleId IdType="pmc">PMC10873417</ArticleId><ArticleId IdType="pubmed">38365933</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M., Peacock T.P., Harvey W.T., Hughes J., Wright D.W., COVID-19 Genomics UK (COG-UK) Consortium. Willett B.J., Thomson E., Gupta R.K., Peacock S.J., et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 2023;21:112–124. doi: 10.1038/s41579-022-00809-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00809-7</ArticleId><ArticleId IdType="pmc">PMC9616429</ArticleId><ArticleId IdType="pubmed">36307535</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19)|Drugs.  [(accessed on 19 June 2024)]; Available online:  https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs.</Citation></Reference><Reference><Citation>Müller T.R., Gao Y., Wu J., Ribeiro O., Chen P., Bergman P., Blennow O., Hansson L., Mielke S., Nowak P., et al. Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. Cell Host Microbe. 2024;32:156–161.e3. doi: 10.1016/j.chom.2023.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.12.010</ArticleId><ArticleId IdType="pubmed">38211584</ArticleId></ArticleIdList></Reference><Reference><Citation>Raisinghani N., Alshahrani M., Gupta G., Verkhivker G. Atomistic Prediction of Structures, Conformational Ensembles and Binding Energetics for the SARS-CoV-2 Spike JN.1, KP.2 and KP.3 Variants Using AlphaFold2 and Molecular Dynamics Simulations: Mutational Profiling and Binding Free Energy Analysis Reveal Epistatic Hotspots of the ACE2 Affinity and Immune Escape 2024. bioRxiv. doi: 10.1101/2024.07.09.602810.2024:2024-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.07.09.602810</ArticleId><ArticleId IdType="pmc">PMC11437503</ArticleId><ArticleId IdType="pubmed">39339934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X.-J., Ji B., Shang C., Li D.-Y., Zhang S., Gu H.-J., Peng H.-H., Qian C., Zhang C.-L., Shi C., et al. Humoral and cellular immune responses following Omicron BA.2.2 breakthrough infection and Omicron BA.5 reinfection. iScience. 2024;27:110283. doi: 10.1016/j.isci.2024.110283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2024.110283</ArticleId><ArticleId IdType="pmc">PMC11260851</ArticleId><ArticleId IdType="pubmed">39040063</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Kempf A., Nehlmeier I., Cossmann A., Richter A., Bdeir N., Graichen L., Moldenhauer A.-S., Dopfer-Jablonka A., Stankov M.V., et al. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell. 2024;187:596–608.e17. doi: 10.1016/j.cell.2023.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.12.025</ArticleId><ArticleId IdType="pmc">PMC11317634</ArticleId><ArticleId IdType="pubmed">38194966</ArticleId></ArticleIdList></Reference><Reference><Citation>Becerra X., Jha A. Project NextGen—Defeating SARS-CoV-2 and Preparing for the Next Pandemic. N. Engl. J. Med. 2023;389:773–775. doi: 10.1056/NEJMp2307867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2307867</ArticleId><ArticleId IdType="pubmed">37494477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmeyer K.A., Ventura C.L., Armstrong K.L., Houchens C.R., Patel S., Disbrow G.L., Johnson R.A., Project NextGen Line of Effort Leads. Bandremer A.C., Beigel J.H., et al. Project NextGen: Developing the Next Generation of COVID-19 Vaccines and Therapeutics to Respond to the Present and Prepare for the Future. Clin. Infect. Dis. 2024;79:115–121. doi: 10.1093/cid/ciae073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae073</ArticleId><ArticleId IdType="pmc">PMC11259220</ArticleId><ArticleId IdType="pubmed">38356144</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo-Romero J.A., Chingaté-López S.M., Camacho B.A., Alméciga-Díaz C.J., Ramirez-Segura C.A. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19. Heliyon. 2024;10:e26423. doi: 10.1016/j.heliyon.2024.e26423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e26423</ArticleId><ArticleId IdType="pmc">PMC10907543</ArticleId><ArticleId IdType="pubmed">38434363</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., Ellebedy A.H. Variant-adapted COVID-19 booster vaccines. Science. 2023;382:157–159. doi: 10.1126/science.adh2712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adh2712</ArticleId><ArticleId IdType="pubmed">37824671</ArticleId></ArticleIdList></Reference><Reference><Citation>SeyedAlinaghi S., Dashti M., Afzalian A., Siami H., Ghasemzadeh A., Varshochi S., Parikhani S.N., Amrollah M.F., Nourian A., Mehraeen E., et al. The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review. Prev. Med. Rep. 2024;44:102778. doi: 10.1016/j.pmedr.2024.102778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2024.102778</ArticleId><ArticleId IdType="pmc">PMC11228787</ArticleId><ArticleId IdType="pubmed">38979481</ArticleId></ArticleIdList></Reference><Reference><Citation>Arimori T., Ikemura N., Okamoto T., Takagi J., Standley D.M., Hoshino A. Engineering ACE2 decoy receptors to combat viral escapability. Trends Pharmacol. Sci. 2022;43:838–851. doi: 10.1016/j.tips.2022.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2022.06.011</ArticleId><ArticleId IdType="pmc">PMC9312672</ArticleId><ArticleId IdType="pubmed">35902282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafari M., Hall M., Golubchik T., Ayoubkhani D., House T., MacIntyre-Cockett G., Fryer H.R., Thomson L., Nurtay A., Kemp S.A., et al. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature. 2024;626:1094–1101. doi: 10.1038/s41586-024-07029-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07029-4</ArticleId><ArticleId IdType="pmc">PMC10901734</ArticleId><ArticleId IdType="pubmed">38383783</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Tantisira K.G. Long COVID and SARS-CoV-2 persistence: New answers, more questions. Lancet Infect. Dis. 2024;24:796–798. doi: 10.1016/S1473-3099(24)00216-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00216-0</ArticleId><ArticleId IdType="pubmed">38663424</ArticleId></ArticleIdList></Reference><Reference><Citation>Machkovech H.M., Hahn A.M., Garonzik Wang J., Grubaugh N.D., Halfmann P.J., Johnson M.C., Lemieux J.E., O’Connor D.H., Piantadosi A., Wei W., et al. Persistent SARS-CoV-2 infection: Significance and implications. Lancet Infect. Dis. 2024;24:e453–e462. doi: 10.1016/S1473-3099(23)00815-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00815-0</ArticleId><ArticleId IdType="pubmed">38340735</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Zepeda S.K., Walls A.C., Greaney A.J., Alkhovsky S., Veesler D., Bloom J.D. ACE2 binding is an ancestral and evolvable trait of sarbecoviruses. Nature. 2022;603:913–918. doi: 10.1038/s41586-022-04464-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04464-z</ArticleId><ArticleId IdType="pmc">PMC8967715</ArticleId><ArticleId IdType="pubmed">35114688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Lv P., Jiang J., Liu Y., Yan R., Shu S., Hu B., Xiao H., Cai K., Yuan S., et al. Advances in developing ACE2 derivatives against SARS-CoV-2. Lancet Microbe. 2023;4:e369–e378. doi: 10.1016/S2666-5247(23)00011-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00011-3</ArticleId><ArticleId IdType="pmc">PMC10019897</ArticleId><ArticleId IdType="pubmed">36934742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–220. doi: 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley L.A., Mezulis S., Yates C.M., Wass M.N., Sternberg M.J.E. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 2015;10:845–858. doi: 10.1038/nprot.2015.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2015.053</ArticleId><ArticleId IdType="pmc">PMC5298202</ArticleId><ArticleId IdType="pubmed">25950237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.E., Chivian D., Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32:W526–W531. doi: 10.1093/nar/gkh468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh468</ArticleId><ArticleId IdType="pmc">PMC441606</ArticleId><ArticleId IdType="pubmed">15215442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigsby R.E., Parker A.B. Using the PyMOL application to reinforce visual understanding of protein structure. Biochem. Mol. Biol. Educ. Bimon. Publ. Int. Union Biochem. Mol. Biol. 2016;44:433–437. doi: 10.1002/bmb.20966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bmb.20966</ArticleId><ArticleId IdType="pubmed">27241834</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue L.C., Rodrigues J.P., Kastritis P.L., Bonvin A.M., Vangone A. PRODIGY: A web server for predicting the binding affinity of protein–protein complexes. Bioinformatics. 2016;32:3676–3678. doi: 10.1093/bioinformatics/btw514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw514</ArticleId><ArticleId IdType="pubmed">27503228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar D., Saville J.W., Sun Z., Zhu X., Marti M.M., Srivastava S.S., Berezuk A.M., Zhou S., Tuttle K.S., Sobolewski M.D., et al. SARS-CoV-2 variants of concern: Spike protein mutational analysis and epitope for broad neutralization. Nat. Commun. 2022;13:4696. doi: 10.1038/s41467-022-32262-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32262-8</ArticleId><ArticleId IdType="pmc">PMC9388680</ArticleId><ArticleId IdType="pubmed">35982054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Xu C., Wang Y., Hong Q., Zhang C., Li Z., Xu S., Zuo Q., Liu C., Huang Z., et al. Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. Nat. Commun. 2021;12:7345. doi: 10.1038/s41467-021-27350-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27350-0</ArticleId><ArticleId IdType="pmc">PMC8688474</ArticleId><ArticleId IdType="pubmed">34930910</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Liu C., Zhang C., Wang Y., Hong Q., Xu S., Li Z., Yang Y., Huang Z., Cong Y. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. Nat. Commun. 2022;13:871. doi: 10.1038/s41467-022-28528-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28528-w</ArticleId><ArticleId IdType="pmc">PMC8847413</ArticleId><ArticleId IdType="pubmed">35169135</ArticleId></ArticleIdList></Reference><Reference><Citation>7V86: Cryo-EM Structure of SARS-CoV-2 S-Kappa Variant (B.1.617.1) in Complex with Angiotensin-Converting Enzyme 2 (ACE2) Ectodomain, Three ACE2-Bound Form.  [(accessed on 11 August 2024)]; Available online:  https://www.ncbi.nlm.nih.gov/Structure/pdb/7V86.</Citation></Reference><Reference><Citation>Nutalai R., Zhou D., Tuekprakhon A., Ginn H.M., Supasa P., Liu C., Huo J., Mentzer A.J., Duyvesteyn H.M.E., Dijokaite-Guraliuc A., et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell. 2022;185:2116–2131.e18. doi: 10.1016/j.cell.2022.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.05.014</ArticleId><ArticleId IdType="pmc">PMC9120130</ArticleId><ArticleId IdType="pubmed">35662412</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Liao H., Meng Y., Li W., Han P., Liu K., Wang Q., Li D., Zhang Y., Wang L., et al. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell. 2022;185:2952–2960.e10. doi: 10.1016/j.cell.2022.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.023</ArticleId><ArticleId IdType="pmc">PMC9212699</ArticleId><ArticleId IdType="pubmed">35809570</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Q., Shi K., Ye G., Zhang W., Aihara H., Li F. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1. J. Virol. 2022;96:e00249-22. doi: 10.1128/jvi.00249-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00249-22</ArticleId><ArticleId IdType="pmc">PMC9044962</ArticleId><ArticleId IdType="pubmed">35343765</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura T., Ito J., Uriu K., Zahradnik J., Kida I., Anraku Y., Nasser H., Shofa M., Oda Y., Lytras S., et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat. Commun. 2023;14:2800. doi: 10.1038/s41467-023-38435-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38435-3</ArticleId><ArticleId IdType="pmc">PMC10187524</ArticleId><ArticleId IdType="pubmed">37193706</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J., Dijokaite-Guraliuc A., Liu C., Zhou D., Ginn H.M., Das R., Supasa P., Selvaraj M., Nutalai R., Tuekprakhon A., et al. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Cell Rep. 2023;42:111903. doi: 10.1016/j.celrep.2022.111903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111903</ArticleId><ArticleId IdType="pmc">PMC9747698</ArticleId><ArticleId IdType="pubmed">36586406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito J., Suzuki R., Uriu K., Itakura Y., Zahradnik J., Kimura K.T., Deguchi S., Wang L., Lytras S., Tamura T., et al. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Nat. Commun. 2023;14:2671. doi: 10.1038/s41467-023-38188-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38188-z</ArticleId><ArticleId IdType="pmc">PMC10175283</ArticleId><ArticleId IdType="pubmed">37169744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni D., Turelli P., Beckert B., Nazarov S., Uchikawa E., Myasnikov A., Pojer F., Trono D., Stahlberg H., Lau K. Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range. PLoS Pathog. 2023;19:e1011206. doi: 10.1371/journal.ppat.1011206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011206</ArticleId><ArticleId IdType="pmc">PMC10109501</ArticleId><ArticleId IdType="pubmed">37018380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdy M.E., El Deeb A.H., Hagag N.M., Shahein M.A., Alaidi O., Hussein H.A. Interspecies transmission of SARS CoV-2 with special emphasis on viral mutations and ACE-2 receptor homology roles. Int. J. Vet. Sci. Med. 2023;11:55–86. doi: 10.1080/23144599.2023.2222981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23144599.2023.2222981</ArticleId><ArticleId IdType="pmc">PMC10334861</ArticleId><ArticleId IdType="pubmed">37441062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Xie Y., Bai B., Luo C., Zhou J., Li W., Meng Y., Li L., Li D., Li X., et al. Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants. Nat. Commun. 2023;14:4405. doi: 10.1038/s41467-023-39942-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39942-z</ArticleId><ArticleId IdType="pmc">PMC10362042</ArticleId><ArticleId IdType="pubmed">37479708</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson S., Lord É., Makarenkov V. Assessing the emergence time of SARS-CoV-2 zoonotic spillover. PLoS ONE. 2024;19:e0301195. doi: 10.1371/journal.pone.0301195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0301195</ArticleId><ArticleId IdType="pmc">PMC10994396</ArticleId><ArticleId IdType="pubmed">38574109</ArticleId></ArticleIdList></Reference><Reference><Citation>Soheili M., Khateri S., Moradpour F., Mohammadzedeh P., Zareie M., Mortazavi S.M.M., Manifar S., Kohan H.G., Moradi Y. The efficacy and effectiveness of COVID-19 vaccines around the world: A mini-review and meta-analysis. Ann. Clin. Microbiol. Antimicrob. 2023;22:42. doi: 10.1186/s12941-023-00594-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-023-00594-y</ArticleId><ArticleId IdType="pmc">PMC10198032</ArticleId><ArticleId IdType="pubmed">37208749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Saikia D., Bankar M., Saurabh M.K., Singh H., Varikasuvu S.R., Maharshi V. Efficacy of COVID-19 vaccines: A systematic review and network meta-analysis of phase 3 randomized controlled trials. Pharmacol. Rep. 2022;74:1228–1237. doi: 10.1007/s43440-022-00429-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-022-00429-1</ArticleId><ArticleId IdType="pmc">PMC9640819</ArticleId><ArticleId IdType="pubmed">36342658</ArticleId></ArticleIdList></Reference><Reference><Citation>Beladiya J., Kumar A., Vasava Y., Parmar K., Patel D., Patel S., Dholakia S., Sheth D., Boddu S.H.S., Patel C. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials. Rev. Med. Virol. 2024;34:e2507. doi: 10.1002/rmv.2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2507</ArticleId><ArticleId IdType="pubmed">38282394</ArticleId></ArticleIdList></Reference><Reference><Citation>Golchin A. Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility. Stem Cell Rev. Rep. 2021;17:56–62. doi: 10.1007/s12015-020-10046-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-020-10046-1</ArticleId><ArticleId IdType="pmc">PMC7532742</ArticleId><ArticleId IdType="pubmed">33009982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S.A., Ho N., Chen S., Chung E.J. Natural Killer Cell-Derived Extracellular Vesicles as Potential Anti-Viral Nanomaterials. Adv. Healthc. Mater. 2024;13:2304186. doi: 10.1002/adhm.202304186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202304186</ArticleId><ArticleId IdType="pubmed">38676697</ArticleId></ArticleIdList></Reference><Reference><Citation>Couto P.S., Al-Arawe N., Filgueiras I.S., Fonseca D.L.M., Hinterseher I., Catar R.A., Chinnadurai R., Bersenev A., Cabral-Marques O., Moll G., et al. Systematic review and meta-analysis of cell therapy for COVID-19: Global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery. Front. Immunol. 2023;14:1200180. doi: 10.3389/fimmu.2023.1200180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1200180</ArticleId><ArticleId IdType="pmc">PMC10321603</ArticleId><ArticleId IdType="pubmed">37415976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreras C., Hernández-Blanco C., Martín-Quirós A., Al-Akioui-Sanz K., Mora-Rillo M., Ibáñez F., Díaz-Almirón M., Cano-Ochando J., Lozano-Ojalvo D., Jiménez-González M., et al. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210) Cytotherapy. 2024;26:25–35. doi: 10.1016/j.jcyt.2023.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2023.10.002</ArticleId><ArticleId IdType="pubmed">37897472</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker R.H., Panettieri R.A., Libutti S.K., Hochster H.S., Watts N.R., Wingfield P.T., Starkl P., Pimenov L., Gawish R., Hladik A., et al. Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. PLoS ONE. 2022;17:e0271066. doi: 10.1371/journal.pone.0271066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0271066</ArticleId><ArticleId IdType="pmc">PMC9273060</ArticleId><ArticleId IdType="pubmed">35816490</ArticleId></ArticleIdList></Reference><Reference><Citation>Havranek B., Lindsey G.W., Higuchi Y., Itoh Y., Suzuki T., Okamoto T., Hoshino A., Procko E., Islam S.M. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Commun. Biol. 2023;6:513. doi: 10.1038/s42003-023-04860-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04860-9</ArticleId><ArticleId IdType="pmc">PMC10177734</ArticleId><ArticleId IdType="pubmed">37173421</ArticleId></ArticleIdList></Reference><Reference><Citation>Torchia J.A., Tavares A.H., Carstensen L.S., Chen D.-Y., Huang J., Xiao T., Mukherjee S., Reeves P.M., Tu H., Sluder A.E., et al. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. Sci. Adv. 2022;8:eabq6527. doi: 10.1126/sciadv.abq6527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abq6527</ArticleId><ArticleId IdType="pmc">PMC9728973</ArticleId><ArticleId IdType="pubmed">36475798</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S., Nelson G., Olson C.A., Buzko O., Higashide W., Shin A., Gonzalez M., Taft J., Patel R., Buta S., et al. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. Sci. Rep. 2021;11:12740. doi: 10.1038/s41598-021-91809-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91809-9</ArticleId><ArticleId IdType="pmc">PMC8211782</ArticleId><ArticleId IdType="pubmed">34140558</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang Y., Wu L., Niu S., Song C., Zhang Z., Lu G., Qiao C., Hu Y., Yuen K.-Y., et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020;181:894–904.e9. doi: 10.1016/j.cell.2020.03.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.045</ArticleId><ArticleId IdType="pmc">PMC7144619</ArticleId><ArticleId IdType="pubmed">32275855</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin G., Akbal-Dagistan O., Culha M., Erturk A., Basarir N.S., Sancar S., Yildiz-Pekoz A. Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. J. Pharm. Sci. 2022;111:2652–2661. doi: 10.1016/j.xphs.2022.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.06.004</ArticleId><ArticleId IdType="pmc">PMC9181835</ArticleId><ArticleId IdType="pubmed">35691607</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews A.A., Ee P.L.R., Ge R. Developing inhaled protein therapeutics for lung diseases. Mol. Biomed. 2020;1:11. doi: 10.1186/s43556-020-00014-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43556-020-00014-z</ArticleId><ArticleId IdType="pmc">PMC7595758</ArticleId><ArticleId IdType="pubmed">34765995</ArticleId></ArticleIdList></Reference><Reference><Citation>Urano E., Itoh Y., Suzuki T., Sasaki T., Kishikawa J., Akamatsu K., Higuchi Y., Sakai Y., Okamura T., Mitoma S., et al. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models. Sci. Transl. Med. 2023;15:eadi2623. doi: 10.1126/scitranslmed.adi2623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adi2623</ArticleId><ArticleId IdType="pubmed">37647387</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiruthani K., Cruz-Teran C., Chan J.F.W., Ma A., McSweeney M., Wolf W., Yuan S., Poon V.K.M., Chan C.C.S., Botta L., et al. Engineering a “muco-trapping” ACE2-immunoglobulin hybrid with picomolar affinity as an inhaled, pan-variant immunotherapy for COVID-19. Bioeng. Transl. Med. 2024;9:e10650. doi: 10.1002/btm2.10650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10650</ArticleId><ArticleId IdType="pmc">PMC11256170</ArticleId><ArticleId IdType="pubmed">39036085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M., Badeti S., Chen C.-H., Pinter A., Jiang Q., Shi L., Zhou R., Xu H., Li Q., Gause W., et al. CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells 2021. BioRxiv. doi: 10.1101/2021.01.14.426742.2021:2021-01</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.14.426742</ArticleId><ArticleId IdType="pmc">PMC8343231</ArticleId><ArticleId IdType="pubmed">34367128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M.T., Jiang Q., Chen C.-H., Badeti S., Wang X., Zeng C., Evans D., Bodnar B., Marras S.A.E., Tyagi S., et al. S309-CAR-NK cells bind the Omicron variants in vitro and reduce SARS-CoV-2 viral loads in humanized ACE2-NSG mice. J. Virol. 2024;98:e00038-24. doi: 10.1128/jvi.00038-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00038-24</ArticleId><ArticleId IdType="pmc">PMC11237809</ArticleId><ArticleId IdType="pubmed">38767356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M., Badeti S., Geng K., Liu D. Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells 2020. BioRxiv. doi: 10.1101/2020.08.11.247320.2020:2020-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.11.247320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M.T., Badeti S., Chen C.-H., Kim J., Choudhary A., Honnen B., Reichman C., Calianese D., Pinter A., Jiang Q., et al. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro. Front. Immunol. 2021;12:652223. doi: 10.3389/fimmu.2021.652223.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.652223</ArticleId><ArticleId IdType="pmc">PMC8343231</ArticleId><ArticleId IdType="pubmed">34367128</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulou I., Rahnama R., Ravich J.W., Seo J., Zolov S.N., Marple A.N., Markovitz D.M., Bonifant C.L. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection. Front. Immunol. 2021;12:763460. doi: 10.3389/fimmu.2021.763460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.763460</ArticleId><ArticleId IdType="pmc">PMC8732772</ArticleId><ArticleId IdType="pubmed">35003077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T., Ma R., Dong W., Teng K.-Y., Kollath D.S., Li Z., Yi J., Bustillos C., Ma S., Tian L., et al. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nat. Commun. 2022;13:2576. doi: 10.1038/s41467-022-30216-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30216-8</ArticleId><ArticleId IdType="pmc">PMC9095674</ArticleId><ArticleId IdType="pubmed">35546150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Gao T., Li W., Tai C., Xie Y., Chen D., Liu S., Huang F., Wang W., Chen Y., et al. Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies. Cell Biosci. 2023;13:160. doi: 10.1186/s13578-023-01099-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-023-01099-z</ArticleId><ArticleId IdType="pmc">PMC10470189</ArticleId><ArticleId IdType="pubmed">37653459</ArticleId></ArticleIdList></Reference><Reference><Citation>Havranek B., Chan K.K., Wu A., Procko E., Islam S.M. Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. J. Chem. Inf. Model. 2021;61:4656–4669. doi: 10.1021/acs.jcim.1c00783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c00783</ArticleId><ArticleId IdType="pubmed">34427448</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaleh M.A., Alsulaiman R.M., Almahboub S.A., Nezamuldeen L., Zawawi A., Aljehani N.D., Yasir M., Abdulal R.H., Alkhaldi R., Helal A., et al. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: A quick therapeutic option for current and future coronaviruses outbreaks. Antib. Ther. 2024;7:53–66. doi: 10.1093/abt/tbad030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abt/tbad030</ArticleId><ArticleId IdType="pmc">PMC10873275</ArticleId><ArticleId IdType="pubmed">38371953</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Iketani S., Li Z., Liu L., Guo Y., Huang Y., Bowen A.D., Liu M., Wang M., Yu J., et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279–286.e8. doi: 10.1016/j.cell.2022.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragonnet-Cronin M., Nutalai R., Huo J., Dijokaite-Guraliuc A., Das R., Tuekprakhon A., Supasa P., Liu C., Selvaraj M., Groves N., et al. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy. Nat. Commun. 2023;14:3334. doi: 10.1038/s41467-023-37826-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37826-w</ArticleId><ArticleId IdType="pmc">PMC10246534</ArticleId><ArticleId IdType="pubmed">37286554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikemura N., Taminishi S., Inaba T., Arimori T., Motooka D., Katoh K., Kirita Y., Higuchi Y., Li S., Suzuki T., et al. Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant 2021. BioRxiv. doi: 10.1101/2021.12.22.473804.2021:2021-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.22.473804</ArticleId><ArticleId IdType="pmc">PMC9097879</ArticleId><ArticleId IdType="pubmed">35471044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y., Yo M.S., Tolentino J.E., Uriu K., Okumura K., Ito J., Sato K. Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants. Lancet Infect. Dis. 2024;24:e482–e483. doi: 10.1016/S1473-3099(24)00415-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00415-8</ArticleId><ArticleId IdType="pubmed">38945150</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyaert M., De Scheerder M.-A., Van Herrewege S., Laureys G., Van Assche S., Cambron M., Naesens L., Hoste L., Claes K., Haerynck F., et al. Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients. Eur. J. Clin. Microbiol. Infect. Dis. 2024;43:177–185. doi: 10.1007/s10096-023-04701-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-023-04701-x</ArticleId><ArticleId IdType="pubmed">37953413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros-Pardo D., Gómez-Puertas P., Marcos-Alcalde Í. STAG2: Computational Analysis of Missense Variants Involved in Disease. Int. J. Mol. Sci. 2024;25:1280. doi: 10.3390/ijms25021280.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25021280</ArticleId><ArticleId IdType="pmc">PMC10816197</ArticleId><ArticleId IdType="pubmed">38279279</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe D.R., Cheatham T.E. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J. Chem. Theory Comput. 2013;9:3084–3095. doi: 10.1021/ct400341p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct400341p</ArticleId><ArticleId IdType="pubmed">26583988</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey W., Dalke A., Schulten K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996;14:33–38. doi: 10.1016/0263-7855(96)00018-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0263-7855(96)00018-5</ArticleId><ArticleId IdType="pubmed">8744570</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>